693257-17-9

Basic information

• Product Name: benzyl 2-(benzyloxy)-4-bromobenzoate
• Synonyms: benzyl 2-(benzyloxy)-4-bromobenzoate
• CAS NO: 693257-17-9
• Molecular Weight: 397.268
• Mol File: 693257-17-9.mol

Chemical Properties

• CAS DataBase Reference: benzyl 2-(benzyloxy)-4-bromobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 2-(benzyloxy)-4-bromobenzoate(693257-17-9)
• EPA Substance Registry System: benzyl 2-(benzyloxy)-4-bromobenzoate(693257-17-9)

Safety Data

• Hazardous Substances Data: 693257-17-9(Hazardous Substances Data)

Upstream product

• 1666-28-0 4-bromosalicylic acid 
• 100-39-0 benzyl bromide 

Downstream Products

• 693257-19-1 2-(benzyloxy)-4-bromobenzoic acid 

Relevant articles and documents

Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor

A pharmacophore model for ATP-competitive inhibitors interacting with the active site of the EGFR protein tyrosine kinase and a putative binding mode of 4-anilinoquinazoline suggest that a salicylic acid function could serve as the pharmacophore replacement of a pyrimidine ring. Superpositions by CAMM of salicylanilides with the potent EGFR tyrosine kinase inhibitor 4-[(3′-chlorophenyl)amino]-6,7-dimethoxyquinazoline showed that salicylanilides should act as tyrosine kinase inhibitors. A series of salicylanilides was synthesized and their inhibitory activity against tyrosine kinases determined. Some of them indeed proved to be potent and selective EGFR tyrosine kinase inhibitors. The most potent ones being 28, 16, 20, 6, and 15, with IC50 in the 23-71 nM range.

SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS

Compounds of the general formula:processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula (I): wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

3-SUBSTITUTED-6-ARYL PYRIDINES

3-substituted-6-aryl pyridines of Formula (I) are provided: Formula (I) wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.